Aviado · Research
Longevity Daily
Monday, May 25, 2026
Listen
Today's Brief
Today's digest has a clear throughline: some of the supplement world's biggest premises are cracking under new evidence. A study in Nature Metabolism — reported by the New York Times — finds that NAD+ blood levels don't actually decline with age, undercutting the core rationale behind billions in NMN and NR sales. A parallel BMJ finding shows calcium and vitamin D pills fail to prevent falls in most older adults, and a New York Times opinion piece notes that brain supplement buyers are chasing scant proof. Peter Attia's new AMA on evaluating medications and supplements couldn't be better timed.
10 stories2 peer-reviewed1 trials
Cognitive Health & Neuroprotection
Brain Supplements Are Booming. The Clinical Evidence Still Isn't There.
A New York Times opinion piece documents that 1 in 5 Americans over 50 are spending billions each year on brain-boosting supplements — despite what the author calls a 'dearth of compelling proof' that products like Focus Factor, BrainMD, and Daily Brain Boost actually work. The piece positions cognitive enhancement as the next major wellness wave after GLP-1 drugs, driven more by anxiety about cognitive decline than by clinical evidence. If your supplement stack includes anything marketed for memory or focus, this is a useful reality check before your next reorder.
Read more →Your Brain Doesn't Avoid Effort — It Avoids Wasted Effort, New Study Finds
A new study upends decades of motivational thinking by showing the brain doesn't naturally avoid effort — it avoids wasted effort, which is a meaningful distinction. This suggests that framing a challenging task as purposeful rather than pointless may work with your brain's actual decision-making architecture rather than against it. The finding has practical implications for exercise adherence, learning protocols, and any cognitive training regimen where motivation is a limiting factor.
Read more →Supplements & Compounds
The Core Claim Behind NAD+ Supplements May Be Wrong, New Study Finds
A study published in Nature Metabolism delivers an uncomfortable challenge to one of the supplement world's fastest-growing categories: blood levels of NAD+ don't actually decline with age, contradicting the central premise used to market billions in annual NMN and NR sales. The New York Times reports that while celebrities and influencers continue to tout these supplements, the scientific rationale has been shakier than the marketing implied. This doesn't prove NAD+ precursors are useless — there may still be tissue-level or functional arguments for investigating them — but the 'replace what age depletes' pitch is now seriously in question. If you're spending $50–100 a month on NAD+ precursors, this finding is a meaningful prompt to revisit your reasoning with your doctor.
Read more →Calcium and Vitamin D Pills Don't Prevent Falls in Most Older Adults, BMJ Study Finds
A major study published in The BMJ finds that daily calcium and vitamin D supplements do not protect most older adults from falls or broken bones — directly challenging a clinical recommendation that has guided practice for decades. The benefit appears limited to specific high-risk subgroups, such as those with confirmed deficiency, rather than the broad population routinely advised to supplement. If you're taking these pills primarily for fracture prevention, it's worth asking your doctor whether your individual risk profile is actually one where the evidence applies.
Read more →Peter Attia's Practical Framework for Deciding What Supplements and Medications Are Actually Worth Taking
In AMA #85, Peter Attia lays out a structured approach for deciding which medications and supplements to take, which to skip, and — critically — how to know if they're working when effects aren't immediately visible, which describes most longevity-oriented interventions. The episode directly tackles the feedback-loop problem: without a biomarker or measurable outcome to track, how do you distinguish a supplement that's working from one that isn't? Given this week's findings on NAD+ and calcium/vitamin D, this is unusually timely listening for anyone managing a supplement protocol.
Read more →Research & Papers
Boosting a Key Longevity Protein Reverses Age-Related Genome Changes in Liver Cells
New research finds that overexpressing Sirtuin 6 (SIRT6), a protein strongly associated with longevity, reverses age-related structural changes in nuclear DNA within liver cells — restoring the chromatin architecture that controls which genes are switched on or off as we age. SIRT6 has been a high-priority target in aging biology for years, and this work strengthens the case that its decline isn't just a marker of aging but a functional driver of it. Worth noting: this is preclinical research, and SIRT6-activating compounds marketed in supplements remain far ahead of robust human evidence.
Read more →The Rise of Zombie-Cell Killers: How Senolytics and Senomorphics Are Entering the Clinic
Dermatology Times surveys the growing field of senotherapeutics — drugs designed to eliminate or suppress the 'zombie' senescent cells that accumulate with age and fuel chronic inflammation throughout the body. The review distinguishes between senolytics (which kill senescent cells by targeting their anti-apoptotic survival mechanisms, including p53 and p21) and senomorphics (which suppress the inflammatory secretions senescent cells emit without killing them outright), with major pharmaceutical players including AbbVie now investigating compounds in clinical trials. For readers tracking the frontier of aging biology, this is a useful map of where the field is heading clinically.
Read more →The Dog Aging Project's Rapamycin Trial May Be Longevity Research's Most Important Ongoing Study
A Newsday feature spotlights the Dog Aging Project's ongoing rapamycin clinical trial — one of the few randomized, controlled longevity drug trials running in large mammals that share our environment, diet, and disease patterns. Researchers are testing whether rapamycin, an mTOR inhibitor approved to prevent organ rejection, can extend healthy lifespan and preserve mobility and cognitive function in aging dogs. The trial is being closely watched by human longevity researchers: dogs may provide faster, more translatable aging data than lab animals and could help build the case for human rapamycin trials.
Read more →Lifestyle & Nutrition
Diet Changes Can Shift Your Biological Age by Years, University of Sydney Research Shows
New reporting from RNZ covers research from University of Sydney nutritional ecologist Alastair Senior showing that dietary changes can measurably shift biological age — defined not by years lived but by how well biomarkers reflect actual physiological function. The research uses the Klemera-Doubal method aging clock, a physiological measure distinct from epigenetic clocks, and finds that diet can meaningfully move the needle across a range of years. The practical implication: what you eat isn't just about disease risk management — it may be directly rewriting how old your body biologically tests.
Read more →Industry & Policy
Singapore Commits $273M to Longevity Research, Putting Brain Health at the Center
Singapore's government is committing SGD$350 million (approximately US$273 million) to healthy longevity research, with brain health and physical function as the primary focus areas. NutraIngredients reports this as one of the more substantial national investments in longevity science, signaling growing government-level recognition that healthspan extension carries significant public health and economic stakes. The initiative is expected to generate meaningful research output — and industry opportunity — in cognitive aging and physical performance over the coming decade.
Read more →